Regeneron (REGN) Misses Q4 EPS by 48c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Roth Affirms Regeneron (REGN) at 'Buy' Following Q4 Results; Sees Opportunity in Shares on Pullback
February 10, 2016 11:53 AM ESTRoth Capital reaffirmed Regeneron (Nasdaq: REGN) at Buy with a price target of $555 after the company reported Q4 EPS of $2.83 and revenue of $1.1 billion, versus consensus estimates calling for EPS of $3.31 and revenue of $1.17 billion, this week.
Analyst Joseph Pantginis commented: REGN's shares have not been immune to the enhanced market turbulence surrounding... More
Leerink Partners Cuts Price Target on Regeneron (REGN) as Eylea Growth Slows
February 10, 2016 8:30 AM ESTLeerink Partners maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN), and cut the price target to $505.00 (from $534.00), following the company's 4Q earnings report. REGN reported weaker than expected 4Q results with soft Eylea growth and guidance, and lower total revenue and pro forma EPS. Regenerons Q4 Eylea revenue had been previously... More
Baird Cuts Price Target on Regeneron (REGN) as Late Stage Trials Hit Operating Costs - Reiterates Outperform
February 9, 2016 1:45 PM ESTBaird maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN), and cut the price target to $526.00 (from $674.00), following the company's 4Q. Non-GAAP EPS missed consensus at $2.81 compared to $3.38. Revenues were lower than expected at $1.10B versus consensus estimates of $1.17B. Mirroring REGN's pre-release in January, U.S.... More
